Casale, T B <br/><br/>
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.  [electronic resource] 

 -  Allergy  02 2018 
 - 490-497 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1398-9995 
<br/><br/><label>Standard No.: </label>10.1111/all.13302  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Anti-Asthmatic Agents--therapeutic use<br/>Asthma--drug therapy<br/>Biological Products--therapeutic use<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Omalizumab--therapeutic use<br/>Patient Selection<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Young Adult